Could a lower dose of a lung cancer drug work just as well with fewer side effects?
NCT ID NCT05037331
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 33 times
Summary
This study tests a lower dose of the targeted therapy osimertinib in people with advanced EGFR-positive non-small cell lung cancer. The goal is to see if the lower dose can still control the cancer while causing fewer side effects. About 58 adults with specific EGFR mutations will take the drug every other day and be monitored for safety and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
National University Hospital
RECRUITINGSingapore, Singapore
Contact
Contact
Conditions
Explore the condition pages connected to this study.